WHO ICTRP trial
The effect of mitiglinide calcium hydrate/voglibose on vascular endothelial…
JPRN-jRCTs071190047 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs071190047 |
|---|---|
| Public title | The effect of mitiglinide calcium hydrate/voglibose on vascular endothelial function and blood glucose fluctuation in patients with type 2 diabetes - Low-dose glimepiride controlled crossover study - |
| Scientific title | The effect of mitiglinide calcium hydrate/voglibose on vascular endothelial function and blood glucose fluctuation in patients with type 2 diabetes - Low-dose glimepiride controlled crossover study - |
| Primary sponsor | Okada Yosuke |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 4 |
| Conditions | Type 2 diabetes mellitus Type 2 diabetes mellitus;Type 2 diabetes mellitus |
| Interventions | mitiglinide/voglibose fixed-dose combination (M/V) precedent group: After 5 days observation period, patients receive treatment with M/V (mitiglinide 10mg/voglibose 0.2 mg, three times a day) for 5 days from the 6th day of study treatment… |
| Registration date | Feb 20, 2020 |
| Target size | 30 |
| Registry page | jrct.niph.go.jp |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: